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ABSTRACT
TREATMENT OF SK-MEL-28 CELLS WITH r-Moj-DM UPREGULATES
PRO-APOPTOTIC GENES P53 AND TNF-β WHILE DOWNREGULATING
ONCOGENE c-Myc
by Melissa C. Lombardo
Cell death by apoptosis is the result of one or multiple signaling pathways that can
be initiated inside or outside the cell for a variety of reasons. Integrins, expressing
themselves on the cell surface, play a central role in some apoptotic pathways. Cancer
cells have been known to bypass this function and upregulate survival factor genes in
order to elude apoptosis and thrive in the body, thus creating an environment in which it
is possible for them to grow and metastasize. Previously in Dr. Soto’s lab, a recombinant
disintegrin mutant, r-Moj-DM, was shown to induce apoptosis in melanoma cell line SKMel-28. To test our hypothesis that r-Moj-DM binds to the β1 integrin subunit, SK-Mel28 cells were treated with a FITC-conjugated antibody anti-β1 and analyzed using flow
cytometry. In order to ascertain which apoptotic pathways are activated by r-Moj-DM,
ten genes, some known pro-apoptotic and some pro-survival, were investigated using RTqPCR. It was confirmed that r-Moj-DM does bind to the β1 integrin subunit, and may
induce apoptosis through that interaction. It was also found that two known proapoptotic genes, p53 and TNF-β, were upregulated in response to treatment with r-MojDM while c-Myc, a known survival factor, was downregulated. This shows the
possibility that the intrinsic pathway may be activated due to a crossover from other
pathways.
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1. Introduction
Disintegrins are small (low molecular weight), non-enzymatic peptides isolated
from venom glands in various genera of viper snakes (Nabi et al. 2014). Disintegrins
bind specifically to integrins expressed on the surface of platelets and other cells,
recognizing the target sequence Arg-Gly-Asp (RGD) binding site as well as other binding
motifs (Pasini et al. 2009; McLane et al. 2004). The RGD motif has been found in
proteins that bind αν and α5β1 integrins (Eda et al. 2015). Disintegrins and recombinant
disintegrins induce changes in cell behavior when bound to particular integrin receptors
(Macêdo et al. 2015; Lucena et al. 2011; Seoane et al. 2010).
Integrins are transmembrane surface receptors that are responsible for cell
adhesion to the extracellular matrix (ECM) by binding to fibronectin, vitronectin,
laminin, or collagen (Keely 2011). Integrins are heterodimeric molecules composed of
one alpha (α) and one beta (β) subunit (Macêdo et al. 2015; Kumar 1998; Hynes 1992).
In humans, different α and β subunits combine to form 24 unique integrin heterodimers
that perform specialized functions on each cell type (Brakebusch et al. 1997).
One important function of integrins is the ability to induce apoptosis. Integrindependent cell adhesion and focal adhesion kinase (FAK) activation can modify the
cytoskeleton shape and activate a MAPK signaling cascade, including downstream Erk
1/2, JNK, and p38 (Saldanha-Gama et al. 2010; Giancotti and Ruoslahti 1999).
Furthermore, integrins play a major role in cancer growth and progression (Plantefaber
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and Hynes 1989). The β1 subunit and ανβ3 integrin are of particular interest (Macêdo et
al. 2015; Seoane et al. 2010).
Disintegrins and recombinant disintegrins have been recognized for their antitumor abilities such as inhibition of angiogenesis, cell proliferation, and cell migration
(Ramos et al. manuscript under journal review; Sánchez et al. 2010; Seoane et al. 2010;
McLane et al. 2008). Recombinant disintegrins maintain their biological activity and can
be mutated to gain different anti-cancer properties (Lucena et al. 2011; Seoane et al.
2010; McLane et al. 2004). For example, Seoane et al. (2010) demonstrated that one
mutant recombinant disintegrin, r-Moj-DM, has remarkable apoptotic action.
Recombinant r-Moj-DM was discovered to also have cell proliferation inhibition abilities
by antagonizing the αν integrin subunit (Ramos et al. in press).
I hypothesized that r-Moj-DM induces apoptosis by targeting an integrin pathway.
To investigate this, ten genes were chosen, in both canonical and newly emerging
apoptotic pathways: ACS, APAF1, Bcl-2, c-myc, DAB2IP, Mcl-1, p38, p53, TNF-β/LTα, and TNXB. Gene expression was measured using qPCR at different time points after
r-Moj-DM treatment to determine if treatment resulted in any alteration of expression.
Understanding the apoptotic mechanisms used by r-Moj-DM will be an essential tool to
further explore ways to induce apoptosis in cancer cells as a possible treatment for many
types of cancer.
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2. Literature Review
2.1. Apoptosis and survival factors drive cell fate
Apoptosis is physically characterized by chromatin clumping referred to as
condensation, DNA fragmentation, mitochondrial rupture, membrane blebbing, and
formation of apoptotic bodies (Brill et al. 1999). Cell death by apoptosis is the result of a
single or multiple signaling pathways that can be initiated inside or outside the cell. Of
interest to this study are two canonical apoptotic signaling pathways: the intrinsic and
extrinsic pathways. Under these two umbrella terms, the individual processes are
extremely complex. There is much overlap in the genes involved in these pathways, and
there are also sub-pathways and signaling cascades.
The Extrinsic Pathway is a receptor dependent pathway. Receptors, namely
tumor necrosis factor receptors (TNFR), Fas, or TRAIL, are embedded in the cell surface
and when activated, a cytoplasmic team of proteins called the death inducing signaling
complex (DISC), assemble. The death domain is responsible for transmitting the signal
to the nucleus to elicit a cellular response to the imposing stimulus. Of the first in the
signaling cascade is caspase 8, which is activated by the death domain. Caspase 8 then
initiates a signaling cascade that results in the activation of caspases 3, 6, 7, and 9. At the
end of this chain of signaling and activation, caspase 3 cleaves CAD (caspase-activated
DNase) translocates into the nucleus and fragments the DNA, sending the cell into
apoptosis (Indran et al. 2011; Pasini et al. 2009; Fulda and Debatin 2006).
The Extrinsic Pathway can also initiate the p38 (also known as the mitogenactivated protein kinase, or MAPK) signal transduction pathway under endoplasmic
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reticulum (ER) stress including UV exposure, aging, genetic mutations, or environmental
conditions. Fas, a member of the death domain complex clustered with tumor necrosis
factor receptors (TNFR), disembarks the complex and initiates p38 (Tobiume et al.
2001). It was also found that Fas forms a trimer with apoptosis signal-regulating kinase 1
(ASK1) and Daxx, thus inducing JNK activation and eventually, the p38 cascade (Chang
et al. 1998).
The Intrinsic Pathway is a receptor independent pathway. Radiation, viral
infections, or drugs can activate this pathway (Pasini et al. 2009). These damaging
stimuli initiate mitochondrial membrane permeabilization (MMP), allowing the release of
cytochrome-c (cyt-c) into the cytosol. Cyt-c induces the activation of caspase 9 via
APAF1. This activation and oligomerization produces the apoptosome, thus activating
caspase 3, resulting in DNA fragmentation and apoptosis (Indran et al. 2011). What
begins as the extrinsic pathway can easily cross over to activate the intrinsic pathway,
since caspase 8 can also activate tBid, which encourages the release of cyt-c from
mitochondria (Indran et al. 2011; Pasini et al. 2009).
Further complicating the apoptotic processes are survival factors that neutralize
the apoptotic signaling proteins. There are many factors that work to prevent apoptosis
once signaling begins in either the extrinsic or intrinsic pathways. Mcl-1, and the Bcl-2
family are excellent examples of these proteins. Bcl-2 has been shown to physically
block apoptotic signaling proteins by directly interacting with and sequestering them
(Indran et al. 2011; Reed 1998). The overexpression of Bcl-2 has been shown to halt
apoptosis in certain cancer cells. This interesting family, consisting of both survival
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factors and pro-apoptotic signalers, has three main functions. First, they dimerize with
other family members to inhibit each other’s activity. For example, Bax and Bcl-2
commonly pair, though Bcl-2 is a known survival factor while Bax is pro-apoptotic (Reed
1998). The proteins will also dimerize with other proteins associated with cell survival or
apoptosis, such as APAF1, protein kinase Raf-1, and the GTPase R-Ras (Reed 1998). It
is speculated that Bcl-2 family proteins can actually regulate APAF1 and that Bcl-2
blocks apoptotic signaling downstream of APAF1 activation in some cell types (Reed
1998; Hengartner 1998). Third, it appears that Bax, Bcl-2, and Bcl-XL are able to form
ion channels. Bax and Bak dimerize, creating mitochondrial pores to release cytochrome
c into the cytosol (Reed 1998).
Mcl-1 is a peptide of interest due it its unique biology and therapeutic
opportunities. Mcl-1 is a highly regulated gene and is regularly expressed during certain
stages of cell differentiation and in response to a number of cell signals (Bingle et al.
2000). A member of the Bcl-2 family, Mcl-1 also acts as a survival factor. Structurally
quite similar to Bcl-2, Mcl-1 has been shown to be extremely important during human
fetal development and essential for the maturation and maintenance of B and T
lymphocytes (Warr and Shore 2008). In cancerous cells, Mcl-1 is primarily localized to
the outer membrane of the mitochondria, where it inhibits the release of cytochrome-C in
the intrinsic pathway of apoptosis (Warr and Shore 2008). It has been demonstrated that
Mcl-1 is upregulated not only in blood cancers such as chronic lymphocytic lymphoma,
but also in solid tumors, particularly in pancreatic cancer, testicular cancer, ovarian
cancer, and melanoma (Warr and Shore 2008). Mcl-1 is required for melanoma cell
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resistance to anoikis, a form of cell death induced when a cell unbinds the extracellular
matrix (Boisvert-Adamo et al. 2009). In 50%-70% of melanoma cells, Sk-Mel-28 cells
included, the serine threonine kinase B-RAF is mutated. This protects malignant
melanoma cells from anoikis. Boisvert-Adamo et al. (2009) found that malignant cells
with the B-RAF mutation and Mcl-1 knocked down had high levels of caspase-3
cleavage. Thus, Mcl-1 mediates the resistance to anoikis in mutant B-RAF melanoma
cells. Further, it has been found by Song et al. (2005) that human non-small cell lung
cancer (NSCLC) solid tumors have elevated Mcl-1 expression when compared with
normal surrounding lung tissue. Mcl-1 was knocked down in NSCLC cells and an
increase in apoptosis was observed, suggesting the gene has a central role in supporting
the survival of these cancer cells. Cells expressing relatively high levels of Mcl-1 were
also found to have increased viability after exposure to cytotoxic agents. Thus, having
emerged as an obvious therapeutic target, chemotherapy drugs such as Sorafenib,
Seliciclib, and Obatoclax have been developed to specifically target Mcl-1 (Warr and
Shore 2008).
Despite these bold developments, Mcl-1 is not as simple as one would think. The
gene also has the ability to undergo differential splicing. Normally transcribed, Mcl-1
has three coding exons; however, there is a variation where first and third exons are
joined, excluding the central one, creating Mcl-1s/ TM (Bingle et al. 2000). This variant
Δ

actually acts as a promoter of cell death.
The fate of each cell is regulated and fought for by the interactions of apoptotic
and survival proteins. In cancer cells, it is seen that survival factors are highly over-
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expressed in order to overcome apoptotic signaling. This contributes to cancer’s ability
to overcome apoptotic signals and achieve a sort of cell immortality (Hanahan and
Weinberg 2011).
2.2. Integrins can induce both anoikis and apoptosis
Integrins are transmembrane surface receptors that are responsible for endothelial
cell adhesion to the extracellular matrix (ECM) by binding to fibronectin, vitronectin,
laminin, and collagen (Keely 2011). If a normal cell becomes detached from the ECM,
the cell undergoes apoptosis due to integrin intracellular signals (Frisch and Francis
1994) and all adherent cells require adhesion to the ECM to advance through the next cell
cycle (Streuli 2009). The structure of tissues is in part due to integrin mediated cell-cell
adhesion with E-cadherin (Keely 2011). The integrin adhesion sites are also the
mounting points for cytoskeletal assembly, and thus control the architecture of the cell
(Streuli 2009). In healthy tissue, when a cell loses its adhesion to E-cadherin and the
cytoskeleton is compromised, the cell undergoes a cell death known as anoikis (Keely
2011). Jun N-terminal kinase (JNK) is increasingly phosphorylated, which activates proapoptotic p53 (Keely 2011; Lane 1992). Cancerous cells are able to metastasize, which
requires breaking away from E-cadherins and the ECM, circumventing the normal
anoikis process. Without this regulation, tumor cells have also been known to degrade
the basal lamina, allowing themselves to invade connective tissue (Keely 2011).
Integrins have two non-covalent components, alpha (α) and beta (β) subunits, and
are therefore called heterodimeric (Macêdo et al. 2015; Kumar 1998; Hynes 1992).
Different α and β units that combine to form unique integrin units that perform specified
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functions on each cell type (Brakebusch et al. 1997). Endothelial cells normally express
combinations of α1, α2, α3, α5, α6, α8, α9, and αν with β1. There are a few other known
α combinations with other β subunits, namely ανβ3 and ανβ5 (Muñoz-Chápuli et al.
2004). All the various combinations of the subunits compose 24 different integrins
(Macêdo et al. 2015; Pasini et al. 2009). Integrin expression is also cell type dependent,
for example, α6β4 is found on epithelial cell surfaces, but not most other cell membranes
(Kumar 1998). These α and β subunits work in tandem and closely associate with
growth factor receptors, among other signaling molecules (Muñoz-Chápuli et al. 2004).
Integrin expression can vary greatly when comparing normal cells to cancer cells
(Macêdo et al. 2015).
Integrins also carry out intracellular signal transduction (Muñoz-Chápuli et al.
2004). Intracellular signals alter the affinity of integrins to their ligands (Dedhar and
Hannigan 1996). There is transfer of information into the cell from the outside, and vice
versa (Brakebusch et al. 1997). Thus, integrins are an extremely important avenue for a
cell to communicate with its environment and trigger signaling pathways that control a
cell’s actions such as mobility, proliferation, death, differentiation, and even morphology
(Streuli 2009; Brakebusch et al. 1997). It makes sense, then, that different integrins are
expressed on the cell membrane at specific points in the cell life cycle and development
(Brakebusch et al. 1997). For example, β1 has been found to play an instrumental role in
myogenesis as well as assist cardiac muscle cell differentiation during fetal development
(Brakebusch et al. 1997). Additionally, the absence of α4 subunits has been shown to
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result in the production of defective white blood cells, namely T-cells and B-cells (Hirsch
et al. 1996).
Yet another important function of integrins is the ability to induce apoptosis.
Integrin-dependent cell adhesion and Focal adhesion kinase (FAK) activation can modify
the cytoskeleton shape and activate MAPK signaling cascade, including downstream Erk
1/2, JNK, and p38 (Saldanha-Gama et al. 2010; Giancotti and Ruoslahti 1999). Upon
binding, FAK autophosphorylates Tyr397, which creates a binding site for Src or Fyn
(Giancotti and Ruoslahti 1999).
Integrin activation also leads to nuclear translocation of NF-κB, a survival factor
also responsible for immune response (Saldanha-Gama et al. 2010). There is also another
opportunity for integrin signaling to contribute to cell survival: FAK-Src complex can
activate PI-3K pathway, which triggers Akt activation. Akt is a survival factor that
inhibits the actions of Bad and Caspase-9 (Giancotti and Ruoslahti 1999). It seems FAK
plays a role in linking connection to the ECM and survival signals. When FAK is
deficient, p53 mediates anoikis signaling (Giancotti and Ruoslahti 1999).
It is no surprise, then, that integrins have been found to play a major role in cancer
formation and progression (Plantefaber and Hynes 1989). The β1 subunit and ανβ3
integrin are of particular interest. The β1 subunit has been shown to play an integral role
in tumorigenesis due to its function in angiogenesis, new blood vessel growth. Bloch et
al. (1997) demonstrated that VEGF (vascular endothelial growth factor) action depends
on functional β1 integrins in teratomas grown on embryonic stem cells. In the absence of
β1, however, teratoma growth is dramatically weakened, suggesting a role in tumor
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proliferation, as well (Brakebusch et al. 1997). Teratoma modifications due to the β1
deficient cells range from increased apoptosis to insufficient angiogenesis. However, it
could be that the increased level of apoptosis is simply due to damaged interaction of the
cell with the ECM due to the subunit deficiency (Brakebusch et al. 1997). Still, the
variation of effects on β1 deficient teratomas suggests that the integrin subunit regulates
different functions in different cell types, perhaps depending upon the α subunit
interaction. This data coincides nicely with Weaver et al.’s study (1997) which found
that breast tumor cells treated with β1 antibodies and injected into mice had significantly
reduced the number and size of successful tumor growth, implicating the integrin in
tumor formation. This has been shown in various additional studies, including one by
Zhang et al. (1995). Chinese hamster ovary (CHO) cells were transfected with a
truncated version of the α5β1 integrin, which lacked the cytoplasmic domain. This cell
line, as well as CHO cells with fully functional α5β1 integrins and CHO cells with ανβ1
integrins were subjected to serum-free fibronectin plate attachment assays. Once the
serum was removed, almost 100% of the CHO cells with truncated α5β1 and ανβ1
integrins showed signs of apoptosis. Less than 25% of the functional α5β1 cells had
become apoptotic within the same time period. The detection of Bcl-2, a well-known
anti-apoptotic agent, was carried out via RT-qPCR. This showed that the mRNA bcl-2
levels were elevated in the functional α5β1 cells, indicating that α5β1 integrin interaction
with fibronectin actually suppresses apoptosis by inducing Bcl-2 upregulation.
The molecular pathways and mechanisms of integrin-triggered cell survival and
apoptosis in cancer cells are still not clear, however, it is known that integrins are
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involved in both tumor progression and restraint. For example, in healthy cells, adhesion
to the ECM activates FAK, which translocates into the nucleus and binds directly to p53
to inhibit p53 function (Keely 2011). In normal cells, p53 is a proapoptotic cell cycle
regulator. However, in many cancers, p53 is mutated and becomes a contributor to tumor
survival (Keely 2011).
During melanoma development, a subset of integrins, including α1β1, α5β1, ανβ3,
and α6β4, directly activates the p38/MAPK pathway (Pasini et al. 2009). Further, ανβ3
has been thoroughly implicated in survival signaling in M21 cells, a melanoma cell line.
Montgomery et al. (1994) concluded that the αν subunit is required in dermal collagen to
avoid apoptosis when the cells are deprived of any external growth factors. Physical
symptoms of apoptosis were observed after only a few days αν (-) M21 cells were placed
in dermal collagen growth environment void of any external growth factors, mimicking
the inner tumor mass environment. This implies that the αν subunit is involved with
survival signaling.
There is currently extensive research being done on the clinical implications of
integrin antagonists as treatments for cancer. One example is Vitaxin, a monoclonal
antibody that interacts with integrin ανβ3. Vitaxin is currently in Phase II clinical trials
for treatment in colorectal cancers due it its ability to inhibit angiogenesis (Eda et al.
2015).
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2.3. Disintegrins bind to integrins and initiate a cellular response
Disintegrins are small (low molecular weight) peptides isolated from snake
venom glands in various genera of venomous snakes (Nabi et al. 2014). Disintegrins are
non-enzymatic peptides that bind specifically to integrins expressed on the surface of
platelets and other cells using the target sequence Arg-Gly-Asp (RGD) binding site as
well as other binding motifs (Pasini et al. 2009; McLane et al. 2004). The RGD site
specifically binds αν and α5β1 integrins, among others (Eda et al. 2015). The binding of
disintegrins to integrins can potentially initiate one or multiple signal transduction
pathways in order to elicit a response from the cell (Keely 2011; Pasini et al. 2009;
McLane et al. 2004), possibly leading to inhibition of platelet aggregation, inhibition of
cell adhesion, angiogenesis, and migration (Lucena et al. 2015).
The functionality of disintegrins depends on the motif in the hairpin loop. There
are three motifs which separate the three functional classes: RGD, MLD (Met-Leu-Asp),
and R/KLS (Arg/Lys-Leu-Ser). Disintegrins with the RGD motif are most common.
Induced or natural variations of the arginine in the RGD motif results in a change or
elimination of the biological effect the disintegrin possesses (Macêdo et al. 2015).
In addition to their functional classes mentioned above, disintegrins are also
separated into structural classes. Commonly, disintegrins are derived from
proteolytically processed precursers called metalloproteases (MPs), or more specifically,
snake venom metalloproteases (SVMPs) (Macêdo et al. 2015). However, some may
result from short coding of mRNAs, which does not have a MP domain. SVMPs are also
sub-categorized into classes based on their domains. The P-I class possesses a MP
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domain only. P-II disintegrins have a MP domain as well as a disintegrin-like domain.
Lastly, the P-III class consists of disintegrins with a MP domain and a cystiene-rich
domain following the disintegrin region (Macêdo et al. 2015).
There is excellent potential for therapeutic uses of disintegrins. Crotalus durissus
terrificus isolated venom disintegrin caused cell death in sarcoma and leukemia (Nabi et
al. 2014). Cytotoxin IIa, a disintegrin isolated from Indian cobra (Naja naja) venom,
exhibited cytotoxicity toward Yoshida sarcoma cells as well as human breast cancer cells
(MCF-7), liver cancer cells (HepG2) and lung carcinoma cells (A549). It is also a potent
in vitro growth inhibitor of MCF-7, HepG2 and A549 cells (Macêdo et al. 2015). Yeh et
al. (1998) found that accutin, another RGD-motif disintegrin, bind to ανβ3 and induce
apoptosis as well as reduce angiogenesis. Teklemariam et al. (2011) have shown that
recombinant acocostatin induces apoptosis in HUVEC and HeLa cells while preventing
cell migration of Sk-Mel-28 cells. Many more disintegrins with useful functional
properties are currently being investigated.
2.4. r-Mojastin Disintegrin
Until recently, only a few disintegrins had been cloned and expressed while
preserving biological activity. Sánchez et al. (2010) exemplified that disintegrins can, in
fact, be cloned and purified utilizing chromatographic techniques to produce functional
biological assays. Crotalus scutulatus scutulatus, the Mohave rattlesnake, contains
venom that is proteolytic, hemorrhagic, and possesses disintegrin activity. Two RGD
disintegrins, mojastin 1 and mojastin 2, were isolated from Mohave rattlesnake venom.
Recombinant mojastin 1 (r-mojastin 1) was produced and compared with the functional
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abilities of the natural mojastin 1 disintegrin. It was found that not only was the
expressed r-mojastin 1 identical in amino acid sequence, but that the natural effects on
adhesion, activation, and platelet aggregation was preserved, albeit less aggressively
(Sánchez et al. 2010).
Shortly after, the anti-tumor properties of r-mojastin 1 were studied extensively.
Human bladder carcinoma cells (T24), fibrosarcoma cells (HT-1080), and melanoma
cells (SK-Mel-28) were used. It was found that r-mojastin 1 inhibited the migration of all
three cell types and inhibited SK-Mel-28 cell adhesion to fibronectin. Further, r-mojastin
1 inhibited invasion of T24 and SK-Mel-28 cells in vitro (Lucena et al. 2011). Later, Rmojastin 1 was also found to inhibit proliferation and cell migration, and induce apoptosis
in human pancreatic adenocarcinoma cells (BXPC-3) (Lucena et al. 2015). Again, this
demonstrates that recombinant mojastin is an extremely useful tool to assist in the study
and development of anti-tumor drugs and agents.
Seoane et al. (2010) compared the functions of three short, recombinant mojastin
disintegrin mutants, r-Moj-WN, r-Moj-NN, and r-Moj-DM, to find a variant that would
successfully induce apoptosis in melanoma cells. It was found that r-Moj-WN and rMoj-NN inhibit platelet aggregation and inhibit SK-Mel-28 cell adhesion to fibronectin.
Recombinant r-Moj-DM was found to induce apoptosis in approximately 15% of
melanoma cells. Gross morphological changes and nuclear fragmentation were observed
by Hoechst staining and differential interference contrast (DIC) microscopy.
Ramos et al. (in press) produced six recombinant r-Moj-D_ mutants containing a
second aspartate carboxyl immediately following the RGD binding motif. Interestingly,
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it appears that each disintegrin mutant possesses different strengths of various biological
activities. For example, all r-Moj-D_ peptides inhibited platelet aggregation, but at
varying potencies. Only three of the six mutants induced apoptosis of SK-Mel-28 cells:
r-Moj-DL, r-Moj-DM, and r-Moj-DN. All three mutants were shown to bind the αν
integrin subunit.
2.5. Emerging apoptotic and survival signals in cancer cells
Hanahan and Weinberg’s (2011) last hallmark, resisting cell death, occurs
because of cancer cell expression of survival factors, also known as anti-apoptotic
signals. Survival factors manage to allow the cell to survive in spite of the numerous
apoptotic signals that may be working to kill the cell. These signaling cascades can be
triggered in multiple ways (Indran et al. 2011).
2.5.1. Bcl-2
Bcl-2 has been found at elevated levels in many types of human cancers,
including blood-based (Fulda and Debatin 2006). Even when cancer cells are exposed to
chemotherapy drugs, Bcl-2 can reduce or even prevent cell death in many cancer types
(Reed 1998). More specifically, Bcl-2 inhibits the release of cytochrome c from the
mitochondria (Green and Reed 1998). Of the Bcl-2 family of proteins, which has at least
16 members, Bcl-2 is arguably the most well known and researched (Reed 1998). For
this reason, it seems necessary to include Bcl-2 in the RT-qPCR studies carried out here.
2.5.2. p53
p53 is a transcriptional regulator that translocates into the nucleus and binds to its
response element (Beckerman and Prives 2010). The main role of p53 is a sequence-
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specific DNA binding protein (Beckerman and Prives 2010). Over 125 protein-coding
genes and noncoding RNAs are direct transcriptional targets of p53, speaking to the
complexity of the p53 signaling network (Beckerman and Prives 2010). During nonstressful times, p53 is maintained at low concentrations and has very little effect on cell
fate (Oren 2003). However, in response to stressors such as replication, DNA damage,
and oncogene activation, p53 determines the appropriate cellular process (Beckerman and
Prives 2010). Thus, p53 can literally determine whether a cell will survive or die, given
the context of p53 activation, by activating other sets of either proapoptotic or prosurvival
genes, depending highly on the cell type and stimulus (Soengas et al. 2001). p53 was the
first tumor suppressor gene linked to apoptosis. Interestingly, p53 mutations occur in the
majority of cancers, augmenting aggressiveness and chemoresistant abilities. However,
these mutations are rarely seen in melanoma cases (Soengas et al. 2001).
Survival signals present in the cell may encourage p53 to lead the cell in the
direction of DNA repair or cell-cycle arrest (Oren 2003). When these signals are absent
or insufficient, it is likely the cell will undergo apoptosis. The molecular pathway for the
activation of the two completely different sets of genes is not well known, though. It is
most likely that multiple mechanisms are involved in p53 target gene selection (Oren
2003). In its pro-apoptotic state, p53 transactivates death receptor genes such as FAS and
DR5 as well as a myriad of apoptotic mitochondrial proteins such as Bax (part of the Bcl
protein family) (Oren 2003).
Inactivation of p53 is extremely important in the formation of cancers due to its
strong tumor suppressor nature (Beckerman and Prives 2010). The simplest way this can
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occur is via a mutation in p53, rendering the protein permanently active. This will also
eradicate all wild-type p53 from the affected cells (Oren 2003). Otherwise, there are
ample opportunities for other proteins in the p53 signaling chain to become mutated. Just
one example is the mdm2 gene, which encodes for a protein that is tightly bound to p53 in
non-stressful times, rendering it inactive (Oren 2003). With the p53 signaling cascade
malfunctioning, the entire Intrinsic Pathway is at risk, and apoptosis signals could be
easily eluded.
Brash et al. (1991) found that 58% of a collection of samples of squamous cell
carcinoma patients from New England, USA and Uppsala, Sweden had a particular type
of p53 mutation. The mutation was base changes CC to TT, which is a distinctive
mutation caused only by UV light. These base pair changes in the p53 gene altered the
amino acid sequence, causing the invasive cancer. The sunlight-driven mutation was
probably not enough to alone induce squamous cell carcinoma, but it certainly played a
major role.
Mcl-1 is upregulated in many melanoma cells, probably as an adaptation to
increased stress on the endoplasmic reticulum (ER) (Jin et al. 2011, Jiang et al. 2008).
Jin et al. propose a novel pathway connecting p53 and Mcl-1 up-regulation. Jin and his
team have found that p53 over expression leads to up-regulation of miRNA-149*, which
plays a central role in targeting Mcl-1 in Mel-RM cells. The over expression of Mcl-1
stabilizes melanoma cells under ER stress. This pathway has yet to be tested in various
other melanoma cell types, such as Sk-Mel- 28, Sk-Mel-2, or HT-144 cells.
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2.5.3. p38 (MAPK)
p38 (or MAPK) is a highly conserved protein. Responding to a multitude of
stimuli, such as growth factors, inflammatory cytokines, heat, osmotic shock, and UV
light, p38 plays a central role in mediating cell stress, much like p53. It is important to
note that p38 activation and action is not only dependent on stimuli, but on cell type, as
well. There are many different upstream activators of p38 kinases, but they are chiefly
activated by partnered kinases called MAP kinases, or MKKs.
Further, two main MKKs are known to directly activate p38: MKK3 and MKK6.
Multiple transcription factors are phosphorylated by p38, notably GADD153 (growth
arrest and DNA damage inducible gene 153), c-Myc, Bcl-2, and p53 (Zarubin and Han
2005; Ivanov and Ronai 2000), all of which are thought to play important roles in cancer
cell survival or apoptosis. p38 has been shown to have a role in post-transcriptional
regulation of inflammatory gene expression, including IL-1β and TNFα. It is no surprise
then, that p38 has been implicated in Rheumatoid arthritis, inflammatory bowel disease,
and Alzheimer’s disease (Zarubin and Han 2005).
In cancer, p38 functionality is complicated and not yet well understood. In some
cell lines, p38 activation seems to promote cell death while in other cell lines, p38 has
been shown to assist in cell survival (Zarubin and Han 2005; Ivanov and Ronai, 2000). It
has been reported that p38 activation may be reduced in tumors, further indicating a
possible role in apoptosis (Zarubin and Han 2005). According to Ivanov and Ronai
(2000) however, in melanoma cell lines LU1205 and WM1552, p38 promotes survival.
They have shown that MKK6 and p38 protect these cell lines from UV-induced apoptosis
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and actually decrease death domain protein expression. Further, the inhibition of p38
lead to a marked increase (up to fourfold) of transcriptional activity by NF-κB and
approximately 3.5-fold increase in the activation of Fas (death domain) promoters.
Because the p38/MAPK signaling process is necessary for the relay of extracellular
signals to the nucleus, some believe that p38 and downstream proteins are overexpressed
in all metastatic melanomas (Pasini et al. 2009).
A novel pathway for p38 apoptotic signaling has been proposed by Zhang et al.
(2007), implicating a new gene holding a vital role in the TNF complex activation. In
human umbilical vein endothelial cells (HUVEC), AIP1 or DAB2IP peptide is essential
for TNF-induced formation of complex 1 (TRAF2-RIP1-DAB2IP-ASK1), ultimately
leading to the activation of p38 apoptotic signaling. Mutation of the DAB2IP binding
site for TNF blocks the complex 1 formation, thus halting p38 MAPK activation. In
short, DAB2IP is a novel protein that seemingly contributes greatly to cell survival
signaling.
2.5.4. DAB2IP
DAB2IP emerged in 2003 as a novel peptide with a central role in TNF-α
signaling (Zhang et al. 2003; Guicciardi and Gores 2003). Also referred to as ASK1interacting protein-1 (AIP1), it is believed that DAB2IP aids in the dissociation of ASK1
from its inhibitor, 14-3-3 in the TNF-α signaling pathway. DAB2IP possibly recruits an
unknown phosphotase to ASK1, which disrupts the ASK1/14-3-3 complex (Zhang et al.
2003). In turn, the JNK or p38 MAPK pathways are activated, which leads to apoptosis
or cell survival. Zhang et al. (2003) have shown that TNF-α activation induces DAB2IP
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interaction with ASK1 in HUVECs. Further, DAB2IP/ASK1 complex formation was
found to increase significantly when TRAF2 expression increased, but not when ASK1
concentrations increased, further supporting their proposed pathway. When DAB2IP was
knocked down in HeLa cells, ASK1 and JNK activation by TNF-α was reduced five- to
seven-fold. This shows the potential importance of DAB2IP to ASK1/JNK activation
and pathway. Later, Zhang and researchers (2004) revised the pathway. They showed
that DAB2IP remains on the cell membrane complexed with TNFR1 in endothelial cells
at rest. Binding of a substrate with TNFR1 releases DAB2IP, and a signaling complex
forms comprised of TRADD, RIP1, TRAF2, and DAB2IP. This pathway functions to
specifically activate ASK1 and, in turn, JNK. Intriguingly, this same complex without
the addition of DAB2IP leads to NF-κB activation instead of JNK. This lead to the
conclusion by Zhang et al. (2004) that DAB2IP is actually responsible for mediating a
balance between JNK activation and NF-κB.
In endothelial cells, the activation of ASK1/JNK induces intrinsic pathway
apoptotic signaling (Zhang et al. 2003). Because DAB2IP enhances JNK activation,
eventually leading to apoptosis, it is believed that DAB2IP acts as an apoptotic signaler
in endothelial cells (Zhang et al. 2004). This is only supported by the findings that
DAB2IP suppressed the expression of NF-κB, a long established survival peptide (Zhang
et al. 2004).
DAB2IP has been found to have a significant impact on prostate cancer cells, as
well. For example, Duggan et al. (2007) may have found a link between a DAB2IP allele
and a more aggressive prostate cancer. In another study, Xie and researchers (2009)
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found that decreased expression of DAB2IP is found in prostate cancer cell lines C4-2
and PC-3. Further, Xie et al. (2009) uncovered that DAB2IP is not only pro-apoptotic
under cell stress, but is also a potent cell growth inhibitor. Later, Xie and colleagues
found that down regulation of DAB2IP promotes tumor proliferation and metastasis
(2010). In fact, a knockdown of the gene in mice initiated the epithelial-to-mesenchymal
transition (EMT), a necessary landmark for prostate tumor cells to metastasize (Xie et al.
2010). DAB2IP has even recently been recognized as a factor in chemotherapy
resistance. DAB2IP knockdown prostate cancer cells showed strong resilience against
several types of drugs (Wu et al. 2013). Interestingly, the opposite was found in C4-2
prostate cancer cells. Increased levels of DAB2IP restored drug sensitivity in that cell
line (Wu et al. 2013).
Since DAB2IP has only begun to be researched, the status of this peptide in many
other cancers, melanoma included, is unknown. Clearly this gene is a promising
therapeutic target in prostate cancer, thus it is reasonable to consider that it may be a
potential target in other cancers, as well.
2.5.5. Cytosolic acetyl-CoA synthetase (ACS)
Cytosolic acetyl-CoA synthetase (ACS) converts long-chain fatty acids into acylCoA during lipid metabolism (Mashima et al. 2009). This enzyme is overexpressed in
many different types of cancers including glioma, colon cancer, and hepatocellular
cancer. The specific role of ACS in cancer cell growth and malignancy is unknown,
however, it is clear that ACS is necessary for glioma cell survival. Even more
interestingly, Mashima and colleagues found that when a glioma cell line was treated
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with Triacsin c, a specific ACS inhibitor, apoptosis was induced. While cytochrome c
was activated, ACS inhibition did not affect levels of Bcl-2, Bcl-XL, and Bax, suggesting
yet another possible non-canonical pathway of apoptosis.
Yoshii et al. (2009) also found that ACS affected tumor cell survival. Four mouse
carcinoma cell lines (Lewis lung, melanoma, colon, and mammary) had higher
expression levels of ACS in hypoxic conditions compared to normoxic. A knockdown of
ACS showed increased tumor cell death when under hypoxia. Further, it was found that
a knockdown of ACS in vivo slowed tumor growth significantly. ACS expression in
human melanoma cells is unknown at this point.
2.5.6. Tenascin-X
In 1993, Bristow et al. described a novel extracellular matrix protein, Tenascin-X.
The peptide is broken up into two segments: TNX-A and TNX-B. TNXB encodes for an
extracellular matrix protein that may be capable of forming multimers. TNXB is highly
expressed in fetal tissues, especially in skeletal, cardiac, and smooth muscle. Though
TNXB does not contain an RGD sequence and hence cannot bind to RGD-dependent
receptors (such as integrins), it may still play an important role in metastasis.
In a study by Matsumoto et al. (2001), TNX-/- mice had normal development and
life spans. Upon injection of B16-BL6, a melanoma cell line, TNX deficient mice
experienced a much more aggressive response. The tumor grew much larger, by
approximately 1.2 fold, than in normal mice. It was also found that TNX deficiency led
to an up-regulation of matrix metalloproteinases (MMPs), which degrade the
macromolecules of the extracellular matrix. The increased expression of MMPs
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encourages rounding and metastasis of the B16-BL6 cells. In fact, pulmonary metastasis
increased by 6.8-fold in TNX-/- mice. This supports previous findings that as malignancy
progresses, TNXB expression decreases. Fujie et al. (2009) had similar findings. In
order to investigate the adhesive properties of TNX, a TNX substrate was treated with
mouse fibroblast L cells. Compared to the PBS control substrate, more than half the L
cells were not adhered at all and of the adhered cells, half of those were rounded and did
not spread. Again, this indicates that TNX promotes detachment and rounding of cells,
leading to metastasis in cancerous cells. Fujie et al. (2009) then found that TNX is a
driving force of the activation of p38 MAP kinase. No activation of the kinase was found
in the PBS substrate cells.
TNXB may also have important diagnostic implications. In 2009, Yuan et al.
found that TNXB is expressed significantly more in malignant mesotheliomas than in
ovarian and breast carcinomas. TNXB levels were even further elevated in
mesotheliomal effusions, again suggesting a role in the inhibition of cellular adhesion to
the extracellular matrix. Yuan et al. (2009) are even calling TNXB a “novel diagnostic
marker” of malignant mesothelioma.
2.5.7. APAF1
In healthy cells, APAF1 is a pro-apoptotic peptide that interacts with cytochrome
c to cleave procaspase 9 into the active form. The active caspase then activates
downstream apoptotic signaling (Lowe and Lin 2000). In 1999, Soengas et al. showed
that APAF1 and Caspase-9, but not p53, are necessary in controlling tumor growth.
When tumor growth was induced in APAF1-/- and Casp9-/- mice, they had appalling

23

tumor volume growth when compared with both wild type and p53-/- mice. According to
Soengas et al. (2001), no mutations in APAF1 have been described as of yet, but in
metastatic melanoma, a highly aggressive and chemoresistant cancer, APAF1 is often
inactivated due to loss of heterozygosity and gene silencing by methylation. This loss of
APAF1 leads to a disabling of the p53 apoptotic signaling cascade, thus giving the cells
power to survive even when treated with doxorubicin, a very common chemotherapy
drug. In Sk-Mel-28 cells, APAF1 was expressed in intermediate amounts (15-30%)
relative to the melanocyte control. In many SK-Mel cell lines, there was zero expression
of APAF1. This contributes immensely to the destructive nature of melanoma and the
failure of treatment with traditional chemotherapy drugs. Soengas’ (2001) conclusions
correspond nicely with Robles’ et al. (2001) findings that p53 directly induces APAF1
gene expression in lymphoblastoid cells responding to stress and, eventually, undergoing
apoptosis. Interestingly, Robles also found that functional p53 is necessary for DNA
damage-induced expression of APAF1 and that p53 can actually transcriptionally activate
APAF1. They have shown that APAF1 is an essential player in the p53 apoptotic
signaling system.
2.5.8. c-myc
c-myc is an oncogene that can potentially induce apoptosis in human cancers. It is
estimated that 70,000 cancer deaths per year in the US are associated with c-myc
mutations (Dang 1999). In healthy cells, c-Myc expression encourages proliferation, but
can also induce apoptosis with help from Bcl-2 (Lowe and Lin 2000). Bcl-2 inhibits cMyc mediated apoptosis in some cells, but this has no effect on proliferative ability of c-
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Myc (Hoffman and Liebermann 1998). Oddly though, overexpression of c-Myc induces
pro-apoptotic Bcl-2 (plus Bcl-2 family members Bax and Bak) independent of p53
activation (Hoffman and Liebermann 2008). Because Bax or Bak is required for
apoptosis signaling via the intrinsic pathway, this means that c-Myc expression helps
govern both intrinsic and extrinsic apoptotic pathways. Essentially, it seems that if
apoptosis is occurring using any canonical pathway, one could expect c-Myc to be
expressed.
Many types of cancers show amplification in c-myc expression, including lung,
breast, and rare cases of colon (Dang and Boxer 2001). c-Myc is a long standing cell
growth mediator, but when interacting with p53 or ARF, becomes a pro-apoptotic signal.
It was shown that ARF and p53 were triggered by ectopic c-Myc expression in murine
embryonic fibroblasts. It does seem that p53 is a necessary component to the apoptotic
pathway, and that c-Myc affects the transcription of other genes that participate in the
apoptotic signaling pathway, such as ornithine decarboxylase, ODC.
In most colorectal cancers, the tumor suppressor gene adenomatous polypsis coli
gene (APC) is rendered inactive. He et al. (1998) propose that c-Myc is highly
overexpressed due to this inactivation, leading to increased β-catenin/Tcf-4 activity. In
turn, this c-myc expression elevation enhances tumor growth.
2.5.9. Lymphotoxin α (LTα, originally named tumor necrosis factor-β, TNF-β )
Lymphotoxin α (LTα, originally named tumor necrosis factor-β, or TNF-β) is a
cytokine that binds and signals through receptors in the tumor necrosis factor family
receptors, TNFR1 and TNFR2 (Etemadi et al. 2013). The TNF “superfamily” aids in
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regulating many cellular processes, including cell death. Historically, it was thought that
LTα was a weaker cell death inducer when bound to TNFR1 when compared to its proapoptotic brother, TNF. However, Etemadi et al. (2013) have concluded that both
cytokines have equal potency to induce cell death and MAPK/p38 pathway activation.
TNFR1 and TNFR2 receptors have been found on most normal and transformed
cells, including endothelial cells and immune cells. LTα seems to be most active with
natural killer cells, B cells, and T cells (Aggarwal 2003). Similarly to most of the
signaling proteins discussed thus far, the TNF family has multiple capabilities, and can
initiate survival and death, depending on a myriad of conditions (Aggarwal 2003).
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3. Methods
3.1. Recombinant r-Moj-DM expression
Seoane et al. first produced the recombinant (r) Moj-DM mutant in 2010. To
grow cells containing the r-Moj-DM mutant, a 1.5 mL tube of the Moj-DM plasmid
containing BL21 cells was thawed and two LB agar plates with ampicillin were streaked
with the cell solution. The plates were incubated for approximately 24 h at 37° C. A
single colony from each plate was chosen, and two tubes of 5 mL of LB broth with 50
mg/mL ampicillin were inoculated with one colony each. The tubes were incubated for
approximately 18 h at 37° C with gentile agitation. Once cell growth was established, 2.5
mL was transferred to 500 mL of prepared, pre-warmed 2xYT broth with 50 mg/mL
ampicillin. To induce expression of the mutant r-Moj-DM, 1.0 mL of 1M IPTG was
added to each flask. After adequate growth was verified by OD600 reading, cells were
pelleted by centrifugation.
3.2. Recombinant r-Moj-DM Isolation
E. coli cell pellets were resuspended in PBS buffer and lysed using sonication.
Separation of r-Moj-DM was performed using glutathione sepharose (GST) bead pulldown technique. The lysate was incubated with GST beads for approximately 16 hours
at 4° C without agitation. The peptide was cleaved from the beads using a thrombin
enzyme capture kit (Novagen). The volume of biotinylated thrombin used was
determined using the formula listed in the manufacturer user guide, which is based on the
estimated protein concentration ascertained by Bradford assay. The presence of purified
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peptide was confirmed using NuPAGE® Novex® SDS-PAGE Bis-Tris Mini Gel
(Invitrogen). Concentration of r-Moj-DM was determined using a Bradford assay.
3.3. SK-Mel-28 Cell Culture
SK-Mel-28 cells were ordered from ATCC (HTB-72). Cells were cultured in T75
flasks in Eagle’s Minimum Essential Media, 10% fetal bovine serum and 5% HyClone
antibacterial and antimicrobial, at 37° C, and 5% CO2.
3.4. Live SK-Mel-28 β 1 Integrin Surface Staining
Cells were cultured to confluency as described above, then trypsinized and
transferred to 6-well plates. Five hundred thousand cells were seeded into each well. The
cells were immediately treated with the following r-Moj-DM concentrations: 20 nM, 40
nM, 60 nM, 80 nM, 100 nM, and 120 nM. These wells were seeded and treated in
triplicate.
After a 5 min incubation period at 37° C, cells were incubated for 10 min with 1%
rabbit blocking serum in PBS solution at room temperature. FITC-labeled antibodies for
integrin β1 were added and incubated for 5 min at 37° C, then in the dark for 30
additional min. Cells were then fixed with 1% formaldehyde and detected using a Becton
Dickinson FACScan flow cytometer. This protocol was previously described in Juliano
et al. (1996).
3.5. RNA Isolation
Approximately 500,000 SK-Mel-28 cells were seeded into each well of an eightwell plate and incubated for approximately 24 h. They were then treated with 5 µM rMoj-DM and incubated for 8-16 h, in 2 h intervals. Two wells were left untreated and
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used as controls. Cells were harvested using cell scrapers and cell pellets were stored at 80° C until RNA isolation. RNA was isolated using Qiagen RNeasy Mini kit.
®

®

Immediately following isolation procedure, the concentration was estimated using a
NanoDrop. To remove any genomic DNA contamination, all RNA was treated with
Ambion DNA-freeTM, exactly as described in the kit user guide.
®

3.6. Reverse Transcription (RT)
To perform reverse transcription (RT), approximately 50 ng of RNA was
incubated for 10 min at 70°C and immediately put on pre-refrigerated cold block for 5
min. Table 1 shows master mix components used to perform RT.

Table 1. Components and volumes used in RT master mix.
Reagent (Starting
Concentration)
First-Strand Buffer, 5x
MgCl2 (50 mM)
dNTPs (10 mM)
DTT (100 mM)
RNase inhibitor (40 U/µL)
Random nonamer (100 µM)
Superscript® II RT (200
U/µL)
FINAL VOLUME

Volume/sample (µL)

Final Concentration

4.0
2.0
2.0
2.0
1.0
5.0
0.5

1x
5 mM
1 mM
10 mM
2 U/µL
25 µM
5 U/µL

16.5

The total volume per sample was brought to 20.0 µL with nuclease-free water
and/or RNA, as shown in Table 2.
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Table 2. RT reaction RNA concentrations and volumes.
Sample ID

Untreated 1
Untreated 2
8 Hours
10 Hours
12 Hours
14 Hours
16 Hours
18 Hours

Original RNA
Concentration
(ng)
18.4
41.4
32.6
37.7
22.7
30.0
23.2
13.6

Vol. RNA
Added to
Reaction (µL)
3.0
1.5
1.7
1.5
2.5
1.7
2.5
3.5

Total RNA in
RT Reaction
(ng)
55.2
62.1
55.4
56.6
56.8
51.0
58.0
47.6

Vol. H2O Added
to RT Reaction
(µL)
0.5
2.0
1.8
2.0
1.0
1.8
1.0
0.0

Thermocycling was completed using Applied Biosystems™ Veriti Thermal
Cycler (Table 3).

Table 3. Thermocycling parameters used for RT reaction.
Step Type (Hold or Cycle)
Hold
Hold
Hold
Hold

Temperature (° C)
20
42
99
0

Time (minutes)
10
45
3
∞

3.7. Real Time PCR Primer Design
cDNA primers were designed using Primer Express software by ABI, with the
exception of Mcl-1 primers, which were taken from Desjobert et al. (2011). cDNA
sequences were obtained on the Ensembl website (www.ensembl.org). Primer pairs were
checked for specificity using NCBI BLAST tool before ordering from Integrated DNA
®

Technologies (IDT) and validated by conventional PCR and gel electrophoresis on 4%
agarose gel to ascertain optimal annealing temperatures (Tm) for each primer pair.
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Table 4. Both primer sequences for each gene investigated (with the exception of
Bcl-2, explained below).
Gene of
Interest
β-actin
(reference
gene)
DAB2IP
ACS
c-Myc
APAF1

Forward Primer

Reverse Primer

GATGAGATTGGCATGGCTTT

CACCTTCACCGTTCCAGTTT

GGCCAGGACTACTGCTTCGA

GGAGGTTCTCCATCCACTTATCC

TCAAAGGCAGTCGGCTCAAC

CTTTGCCTTCCCTTGCAATG

CTGCTGGGAGGAGACATGGT

CCACATACAGTCCTGGATGATGA

GGCATTCCTGTTGTCTCTTCTTC

TACTCCACCTTCACACAGGACTGT

AGCTGCATCGAACCATTAGC

TCCTGATGCCACCTTCTAGG

Mcl-1
TNF-β
TNX-B
p53
p38

GTTCCCCAGGGACCTCTCTCT

ACATGGGCTACAGGCTTGTCA

GGAAGCCCCTCTTCTCAGCTT

AGGTTAATGCGGTGGGTGAA

CCCCTCCTCAGCATCTTATCC

GCACCACCACACTATGTCGAA

TGGCTCTGTGTGTGCTGCTT

TTCGCATGAATGATGGACTGA

Product
Size

100bp
97bp
90bp
93bp
90bp
136bp
90bp
80bp
90bp
93bp

To analyze Bcl-2, a different method was used due to difficulty designing
acceptable primers. A TaqMan® Gene Expression Assay (assay ID Hs00608023_m1)
from Life Technologies was purchased. The corresponding β-actin assay was purchased
(assay ID Hs99999903_m1) and used as a control or reference gene. Bcl-2, along with
Mcl-1, ACS, c-myc, and TNX-B are survival factors while the others (DAB2IP, APAF1,
TNF-β, p53, and p38) are known to be pro-apoptotic. β-actin was used as a reference
gene for each gene tested.
3.8. Real Time (Quantitative) PCR
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A master mix of the following components was made, as shown in the table
below.

Table 5. Components and volumes of SYBR Green master mix used for real time
PCR
Reagent Added
SYBR Green iQ SuperMix
Nuclease free H2O
Forward primer
Reverse primer

Volume Added (µL) per Reaction
7.5
4.5
1.0
1.0

Fourteen microliters of master mix was pipetted into each well of a 96 well plate,
following the layout in Figure 4 below. One microliter of cDNA from section 3.1.1 was
added to the appropriate wells, following the layout in Figure 4 below.

Figure 1. Layout example of 96-well plate for each gene of interest (GOI) tested.

An ABI 7500 Quantitative PCR System was used for qPCR analysis. The
thermocycling program is shown below. Data was taken for 40 PCR cycles.
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Table 6. Real Time (quantitative) Thermocycling Parameters
Step Type (Hold or Cycle)
Hold
Cycle, Step 1
Cycle, Step 2
Cycle, Step 3

Temperature (°C)
95
95
60
72

Time seconds)
180
10
30
30

Following the above program, the melt curve analysis program was run. This was
comprised of 80 cycles of 55 + 0.50 C per cycle.

3.9. Real Time PCR Data Analysis
Threshold cycle number (Ct) was automatically determined by Applied
Biosystem software, but was checked for accuracy. qPCR data was analyzed using the
comparative Ct method as described by Schmittgen and Livak (2008). The exact formula
to ascertain the ΔΔCt is below.
ΔΔCt = (Ct(target, untreated) – Ct(reference, untreated)) – (Ct (target, treated) – Ct(reference, treated))
Fold difference was calculated as 2-ΔΔCt.
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4. Results
4.1. Expression of mutant r-Moj-DM
r-Moj-DM was successfully isolated and purified, then visualized by SDS-PAGE
gel (Fig. 2). A single band of ~8.2 kDa was observed, as shown in Figure 2.

1

2

3

Figure 2. Purified r-Moj-DM. Lanes 1-3: r-Moj-DM (~8.2 kDa). Lane 5: Invitrogen
Protein Molecular Weight Standard.

4.2. Primer Design and Tm Optimization
All the primers for the genes of interest, with the exception of Bcl-2, were
successfully designed and the annealing temperatures (Tms) were determined. Primers
were designed and tested using conventional, gradient PCR to ascertain the optimal Tm
for each primer pair. PCR products were separated on a 4% agarose gel (Fig. 3). Primer
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pairs with optimal Tms showed a single band, signifying that no nonspecific products
were amplified.

A

B

Figure 3. An example photo of a gradient gel run with 25bp DNA marker. Gel shows
PCR products of the following: Lane M: 25bp ladder; Lane 1: p38 at 62° C Tm; Lane 2:
TNF-B at 62° C Tm; Lane 3: TNX-B at 62° C Tm; Lane 4: ACS at 63° C Tm; Lane 5:
Mcl-1 at 63° C Tm, Lane 6: p38 at 63° C Tm, Lane 7: p53 at 63° C Tm, Lane 8: TNF-B
at 63° C Tm, Lane 9: TNX-B at 63° C Tm, Lane 10: Blank. Lanes 6 and 7 show single
bands.
4.3. Binding Analysis of SK-Mel-28 Staining of β1 Integrins
In order to confirm r-Moj-DM binds to the β1 integrin, SK-Mel-28 cells were
treated with varying concentrations of r-Moj-DM and live stained. Cells were analyzed
using a Becton Dickinson FACScan flow cytometer and analyzed using Cell QuestPro
and FloJo software. The presence of β1 integrins on SK-Mel-28’s surface was previously
confirmed by Seoane et al. (2010). β1 integrin staining revealed FITC decreases in
relation to the untreated cells, as shown in Figure 4 below.
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*

Figure 4. r-Moj-DM binds to the β1 integrin subunit of SK-Mel-28 cells. Flow cytometry
and FITC-conjugated anti-β1 antibodies were used to detect β1 expression on untreated
SK-Mel-28 cells, and cells treated with r-Moj-DM at 20 nM, 40 nM, or 60 nM. β1
integrin detection on untreated cells (*).
4.4. Real Time qPCR Gene Expression Analysis
A total of ten genes, a combination of survival factors and pro-apoptotic factors,
were tested using SYBR Green or TaqMan RT-qPCR (Figure 5).
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Figure 5. (A) Amplification plot of c-myc and β-actin (control) expression exported
from data. All other gene amplification plots looked similar. (B) Melt curve exported
from data showing melting temperature of c-myc and β-actin (control). Nonspecific
noise is from wells containing no-RT controls and NTCs. All other melt curve plots
looked similar.
For each time point, the ΔΔCt and fold difference was calculated as described in
Methods (3.9) to determine any differences in expression of any gene over treatment
time. The findings were then separated according to pro-apoptotic or survival factor
family.
A total of ten genes were tested. Of the five survival factors, Bcl-2, TNX-B, Mcl1, and ACS showed no significant changes in expression (under 1.9-fold change) when
compared with the untreated cells (Figure 6). c-Myc, however, was found to be
downregulated by approximately 13-fold after 8 hours of treatment (Figure 7).
Five total pro-apoptotic genes were also tested. Of this group, DAB2IP, c-Myc,
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and APAF1 showed no significant changes (under 1.9-fold change) in expression when
compared with the untreated cells (Figure 6).

Figure 6. Low expression of survival and pro-apoptotic genes after treatment with
r-Moj-DM. Black bars denote pro-apoptotic genes and grey bars show survival
genes.
p53 showed an increase in expression ranging from 5-fold to 8-fold over the 8 to
18 hour treatment period. TNF-β expression increased 33-fold after 8 hours and 81-fold
after 18 hours of treatment (Figure 8).
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Figure 7. Oncogene c-Myc was downregulated after 8 hours of treatment with r-MojDM.

Figure 8. Pro-apoptotic genes p53 and TNF-β are overexpressed after 8 hours of
treatment with r-Moj-DM.
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5. Discussion
This study was completed with two objectives: to determine if r-Moj-DM binds to
the β1 integrin, and to determine which potential gene targets that are down- or
upregulated as a result of r-Moj-DM 8-18 hours after treatment.
5.1. Live SK-Mel-28 β 1 Integrin Surface Staining
Seoane et al. (2010) determined that SK-Mel-28 cells express αvβ3 and the
integrin subunit β1 on its cell surface. Ramos et al. (in press) present evidence indicating
that r-Moj-DM binds to the αvβ3 receptor, but not very efficiently. The authors
hypothesized that r-Moj-DM could exert some its activity through α6β1, an integrin
expressed on SK-Mel-28. The integrin subunit β1 has been implicated in tumor invasion
and it is expressed on metastatic melanoma cells (Mizejewski 1999). Here, I present
findings provide support to the hypothesis presented in Ramos et al. (in press), as r-MojDM binds to the β1 subunit. It remains to be determined if some of the apoptotic activity
exerted by r-Moj-DM is activated by its binding to the β1 or α6 subunits.
At least 26 lines of melanoma cells exist (ATCC 2016), each potentially having
different integrin expression patterns. It is imperative to study integrin expression on all
those cell lines and study their role in survival and apoptosis to better develop targeted
therapies. Integrins show much promise for alternative treatment options for a wide
variety of cancer patients (Eda et al. 2015; Nabi et al. 2014).
5.2. Real Time (Quantitative) PCR
In healthy cells, p53 initiates the apoptotic process when environmental stress or
DNA abnormalities are present (Beckerman and Prives 2010; Soengas et al. 2001).
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Many types of cancer cells have mutations in p53, attesting to the immortal and
aggressive nature of these cancers. In melanomas, however, this particular mutation is
not common and p53 is wild type in SK-Mel-28 cells (Soengas and Lowe 2003). p53 is
upregulated in SK-Mel-28 cells after treatment with the snake venom jararhagin (Klein et
al. 2011). Further, it was found that chemotherapy-induced apoptosis is p53-dependent
in melanoma cells (Li et al. 2000; Li et al. 1998). This supports our current findings of
upregulation of p53 after treatment with r-Moj-DM.
c-Myc is a known survival factor or oncogene; thus it makes sense that while
undergoing apoptosis, a downregulation would be seen (Evan and Vousden 2001). Many
contradictory results have been found concerning the link of melanoma growth to c-Myc
expression (Kraehn et al. 2001). While its expression is tightly controlled in normal
cells, it is often deregulated in tumor cells (Evan and Vousden 2001). One study by
Kraehn et al. (2001) found that the ratio of expression of c-Myc to the centromere of
chromosome 8 was 1.0, indicating no upregulation is present in this cell type. According
to Zhuang (2008), c-Myc levels in melanoma cell lines show a 3- to 20-fold increase
when compared with normal melanocytes. Further, Zhuang (2008) proposes even >70%
decrease of c-Myc expression could be sufficient to send the cell into senescence. It
would be interesting to study the effects of r-Moj-DM on c-Myc directly to determine
whether SK-Mel-28 cells are undergoing apoptosis or senescense. A knockdown of cMyc in SK-Mel-28 cells could also offer some information regarding the exact role in
some SK-Mel-28 cell survival after treatment with r-Moj-DM. More testing needs to be
completed to determine a more clear role of c-Myc in this interaction.
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LTα/TNF-β is a cytokine that binds and signals through receptors in the tumor
necrosis factor family receptors, TNFR1 and TNFR2 (Etemadi et al. 2013). The TNF
superfamily aids in regulating many cellular processes such as cell death by a variety of
pathways. My findings suggest the potential involvement of the p53 (intrinsic) signaling
apoptotic process in r-Moj-DM treated SK-Mel-28 cells, possibly crossing over to the
p53 intrinsic pathway from the TNF-β/TNFR1 (extrinsic) binding complex. However,
more studies need to be completed, such as a knockdown of TNF-β or TNFR1. Also
helpful in drawing a full picture of the molecular process induced by r-Moj-DM would be
a full apoptotic and survival gene analysis by RNA sequencing after 8 hours of r-MojDM treatment. Further, it would be interesting to see if caspases are still activated
despite the absence of APAF1 upregulation, as was found by Chen et al. (2001). This
would also implicate a crossover to the intrinsic pathway independent of APAF1
activation, possibly via caspase 8.
Previous analysis of SK-Mel-28 cells treated with r-Moj-DM found another set of
genes to be affected after a short treatment (1-6 hours) (unpublished data). Here, we
propose a new model of apoptosis in SK-Mel-28 cells including one set of genes that are
upregulated early after treatment, and another set that is upregulated later (8 hours) after
treatment (Fig. 9). TNXIP-1 is a known pro-apoptotic gene that was shown to be
upregulated after 6 hours of treatment with r-Moj-DM, while survival factors IGFBP-3,
Prune-2, and TGFβ-1 were found to be downregulated.
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Figure 9. Proposed model of early and late response genes after treatment with
disintegrin r-Moj-DM on SK-Mel-28 cells. After 6 hours of treatment, TXNP-1 was
highly upregulated while two other known pro-apoptotic genes, BNIP-3 and PTPSF,
were downregulated. Survival factors IGFBP-3, Prune-2, and TGFβ-1 were
downregulated 6 hours after treatment. After 8 hours of treatment, c-Myc was
downregulated.
Bcl-2 is a known potent survival factor, and physically blocks apoptotic signaling
proteins by directly interacting with and sequestering them (Indran et al. 2011; Reed
1998). The overexpression of Bcl-2 has been shown to halt apoptosis in certain cancer
cells. In my study, Bcl-2 did now show high levels (under 1.4-fold change) of expression
in SK-Mel-28 cells. However, these findings are not surprising. Malignant melanoma
cells, including the SK-Mel-28 cell line, also showed reduced Bcl-2 expression levels
(Placzek et al. 2010; Tang et al. 1998). One study by Chen et al. (2001) revealed Bcl-2
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highly upregulated in SK-Mel-28 cells 36 hours after being treated with a polyamine
analogue. It is possible that I could have found similar results if the time points of my
study been expanded beyond 18 hours. It is important to note that the karyotype of SKMel-28 cells is complex: a 4n-hypotetraploid (Reinhold 2012). This should also be
considered when comparing to other cell line expression changes as missing
chromosomes and rearrangements could effect expression patters.
The expression of apoptotic and survival proteins seem to vary not only with cell
types, but also with the stage of progression the cancer cell is in. For example, Mcl-1
expression is found in 70-80% of normal skin cells, but 60% of small (under 1 mm in
size) primary melanomas. In larger melanomas (over 1 mm in size), Mcl-1 expression
swells to 95%. When these cells metastasize, 100% show Mcl-1 expression (Hartman
and Czyz 2013; Placzek et al. 2010). This pattern makes sense as Mcl-1 protects cells
from anoikis (Hartman and Czyz 2013).
It is shown here and in previous studies that r-Moj-DM has great potential as a
SK-Mel-28 fighting agent. The complexity of the molecular pathways involved in
apoptosis and cell survival are complex, sometimes contradictory, and varies with every
cell type and stage of cell growth, particularly in cancer. It is imperative that more
research be done to elucidate utilized survival and apoptotic pathways in different cancer
cells to develop more effective means for patients’ treatment.

44

References
Aggarwal BB. 2003. Signaling pathways of the TNF superfamily: A double edged sword.
Nature Reviews 3:745-57.
Beckerman R and Prives C. 2010. Transcriptional regulation by p53. Cold Spring Harb
Perspect Biol 2:1-16.
Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MKB. 2000. Exon
skipping in mcl-1 results in a bcl-2 homology domain 3 only gene product that
promotes cell death. J Biol Chem 275:22136-46.
Bloch W, Forsberg E, Lentini S, Brakebusch C, Martin K, Krell HW, Weidle UH,
Addicks K, Fässler R. 1997. B1 integrin is essential for teratoma growth and
angiogenesis. Jour of Cell Biol 139(1):265-78.
Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. 2009. Mcl-1 is required for
melanoma cell resistance to anoikis. Mol Cancer Res 7(4):549-56.
Brakebusch C, Hirsch E, Potocnik A, Fässler R. 1997. Genetic analysis of B1 integrin
function: Confirmed, new and revised roles for a crucial family of cell adhesion
molecules. Jour of Cell Sci 110:2895--2904.
Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten
J. 1991. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous
cell carcinoma. Proc Natl Acad Sci USA 88:10124-8.
Brill A, Torchinsky A, Carp H, Toder V. 1999. The role of apoptosis in normal and
abnormal embryonic development. Jour of Asst Repr and Gen 16(10):512-9.
Bristow J, Tee MK, Gitelam SE, Mellon SH, Miller WL. 1993. Tenascin-X: A novel
extracellular matrix protein encoded by the human XB gene overlapping P450c21B.
Jour of Cell Biol 122:265-78.
Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. 1998. Activation of apoptosis
signal – regulating kinase 1 (ASK1) by the adapter protein daxx. Science 281:18603.
Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. 2001. Apoptotic signaling in
polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res
61:6437-44.
Dang CV. 1999. c-myc target genes involved in cell growth, apoptosis, and metabolism.
Mol and Cell Bio 19(1):1-11.

45

Dang CV and Boxer LM. 2001. Translocations involving c-myc and c-myc function.
Oncogene 20(40):5595-5611
Dedhar S and Hannigan GE. 1996. Integrin cytoplasmic interactions and bidirectional
transmembrane signaling. Curr Opin Cell Biol 8:657-69.
Desjobert C, Renalier M, Bergalet J, Dejean E, Joseph N, Kruczynski A, Soulier J,
Espinos E, Meggetto F, Cavaillé J, et al. 2011. MiR-29a down-regulation in ALKpositive anaplastic large cell lymphomas contributes to apoptosis blockade through
MCL-1 overexpression. Blood 117(24):6627-37.
Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C,
Isaacs SD, Cheng Y, Li G, et al. 2007. Two genome-wide association studies of
aggressive prostate cancer implicate putative prostate tumor suppressor gene
DAB2IP . JNCI J Natl Cancer Inst 99(24):1836-44.
Eda SR, Kumar DS, Jinka R. 2015. Parmacological and clinical importance of integrin
antagonists in treatment of cancer. J Cell Sci Ther 6(1):193.
Etemadi N, Holien JK, Chau D, Dewson G, Murphy JM, Alexander W, S., Parker MW,
Silke J, and Nachbur U. 2013. Lymphotoxin a induces apoptosis, necroptosis, and
inflammatory signals with the same potency as tumour necrosis factor. FEBS Journal
280:5283-97.
Evan GI and Voussen KH. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature
411:342-48.
Frisch SM and Francis H. 1994. Disruption of epithelial cell-matrix interactions induces
apoptosis. Jour of Cell Biol 124(4):619-26.
Fujie S, Maita H, Ariga H, Matsumoto K. 2009. Tenascin-X induces cell detachment
through p38 mitogen-activated protein kinase activation. Biol Pharm Bull
32(10):1795-9.
Fulda S and Debatin KM. 2006. Extrinsic versus intrinsic pathways in anticancer therapy.
Oncogene 25:4798-811.
Giancotti FG and Ruoslahti E. 1999. Integrin signaling. Science 285:1088-32.
Green DR and Reed JC. 1998. Mitochondria and apoptosis. Science 281:1309-12.
Guicciardi ME and Gores GJ. 2003. AIP1: A new player in TNF signaling. J of Clin
Invest 111:1813-5.

46

Hanahan D and Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell
144(5):646--674.
Hartman ML and Czyz M. 2013. Anti-apoptotic proteins on guard of melanoma cell
survival. Cancer Letters 331:24-34.
He T, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B,
Kinzler KW. 1998. Identification of c-MYC as a target of the APC pathway. Science
281:1509-12.
Hengartner MO. 1998. Apoptosis: Death cycle and swiss army knives. Nature 391:441-2.
Hirsch E, Iglesias A, Potocnik AJ, Hartmann U, Fässler R. 1996. Impaired migration but
not differentiation of haematopoietic stem cells in the absence of bold B1 integrins.
Nature 380:171-5.
Hoffman B, Liebermann DA. 2008. Apoptotic signaling by c-MYC. Oncogene 27:646272.
Hoffman B, Leibermann DA. 1998. The proto-oncogenic c-myc and apoptosis. Oncogene
17:3351-7.
Hynes RO. 1992. Integrins: Versitility, modulation and signaling in cell adhesion. Cell
69:11-25.
Indran IR, Tufo G, Perviaz S, Brenner C. 2011. Recent advances in apoptosis,
mitochondria, and drugh resistance in cancer cells. Bba 1807:735-45.
Ivanov V and Ronai Z. 2000. p38 protects human melanoma cells from UV-induced
apoptosis through down-regulation of NF-kB activity and fas expression. Oncogene
19:3003-12.
Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, Thorne RF, Allen J, Hersey
P, Zhang XD. 2008. Up-regulation of mcl-1 is critical for survival of human
melanoma cells upon endoplasmic reticulum stress. Cancer Res 68(16):6708-15.
Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, Zhang LJ, Thorne RF, Wilmott J,
Scolyer RA, et al. 2011. MicroRNA-149*, a p53-responsive microRNA, functions as
an oncogenic regulator in human melanoma. Pnas 108(38):15840-5.
Juliano D, Wang Y, Marcinkiewicz C, Rosenthal LA, Stewart GJ, Niewiarowski S. 1996.
Disintegrin interaction with avB3 Integrin on human umbilical vein endothelial cells:
Expression of ligand-induced binding site on B3 subunit. Exper Cell Res 225:132-41.

47

Keely PJ. 2011. Mechanisms by which the extracellular matrix and integrin signaling act
to regulate the switch between tumor suppression and tumor promotion. J Mammary
Gland Biol Neoplasia 16:205-19.
Klein A, Capitanio JS, Maria DA, Ruiz IR. 2011. Gene expression in SK-mel-28 human
melanoma cells treated with the snake venom jararhagin. Toxicon 57(1):1-8.
Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU.
2001. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and
melanoma metastases. Brit Jour of Cancer 84(1): 72-9
Kumar CC. 1998. Signaling by integrin receptors. Oncogene 17:1365-73.
Lane DP. 1992. Cancer. p53, guardian of the genome. Nature 358:15-6.
Li G, Tang L, Zhou X, Tron V, Ho V. 1998. Chemotherapy-induced apoptosis in
melanoma cells is p53 dependent. Melanoma Res 8(1):17-23.
Li G, Bush JA, Ho VC. 2000. p53-dependent apoptosis in melanoma cells after treatment
with camptothecin. J Invest Dermatol 114:514-9.
Lowe SW and Lin AW. 2000. Apoptosis in cancer. Carcinogenesis 21(3):485-95.
Lucena SE, Sánchez EE, Pérez JC. 2011. Anti-metastatic activity of the recombinant
disintegrin, r-mojastin 1, from the mohave rattlesnake. Toxicon 57:794-802.
Lucena SE, Castro R, Lundin C, Hoffstetter A, Alaniz A, Suntravat M, Sánchez EE.
2015. Inhibition of pancreatic tumoral cells by snake venom disintegrins. Toxicon
93:136-43.
Macêdo JK Arruda, Fox JW, de Souza Castro M. 2015. Disintegrins from snake venoms
and their applications in cancer research and therapy. Curr Protein and Peptide Sci
16:532-48.
Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y, Tsuruo T, Seimiya H.
2009. Acyl-CoA synthetase as a cancer survival factor: Its inhibition enhances the
efficacy of etoposide. Cancer Sci 100(8):1556-62.
Matsumoto K, Takayama N, Ohnishi J, Ohnishi E, Shirayoshi Y, Nakatsuji N, Ariga H.
2001. Tumor invasion and metastasis are promoted in mice deficient in tenascin-X.
Genes to Cells 6:1101-11.
McLane MA, Joerger T, Mahmoud A. 2008. Disintegrins in health and disease. Front in
Biosci 13:6617-37.

48

McLane MA, Sanchez EE, Wong A, Paquette-Straub C, Perez JC. 2004. Disintegrins.
Curr Drug Targets Cardiovasc Haematol Disord 4:327-55.
Mizejewski GJ. 1999. Role of integrins in cancer: Survey of expression patterns. P s e b
m 222:124-38.
Montgomery AMP, Reisfeld RA, Cheresh DA. 1994. Integrin avB3 rescues melanoma
cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA
91:8856-60.
Muñoz-Chápuli R, Quesada, AR, Medina MA. 2004. Angiogenesis and signal
transduction in endothelial cells. Cell. Mol. Life Sci. 61:2224-43
Nabi G, Ahmad I, Hussain A, Khan S, Ahmad S. 2014. An overview on snake venom
anti-cancer activity. Ijiar 2(12):17-22.
Oren M. 2003. Decision making by p53: Life, death, and cancer. Cell Death & Diff
10:431-42.
Pasini L, Turco MY, Luzi L, Aladowicz E, Fagiani E, Lanfrancome L. 2009. Melanoma:
Targeting signaling pathways and RaLP. Expert Opin Ther Targets 13(1):93-104.
Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. 2010. A survey of the antiapoptotic bcl-2 subfamily expression in cancer types provides a platform to predict
the efficacy of bcl-2 antagonists in cancer therapy. Cell Death and Disease 1(e40):19.
Plantefaber LC and Hynes RO. 1989. Changes in integrin receptors on oncogenically
transformed cells. Cell 56(2):281-90.
Ramos CJ, Gutierrez DA, Aranda AS, Koshlaychuk MA, Carrillo DA, Medrano R,
McBride TD, U A, Medina SM, Lombardo MC, Lucena SE, Sanchez EE, Soto JG.
2016. Functional characterization of six aspartate (D) recombinant mojastin mutants
(r-Moj): a second aspartate amino acid carboxyl to the RGD in r-Moj-D_ peptide is
not sufficient to induce apoptosis in SK-Mel-28 cells. Toxicon (in press)
Reed JC. 1998. Bcl-2 family proteins. Oncogene 17:3225-36.
Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, and
Pommier Y. 2012. CellMiner: A web-based suite of genomic and pharmacologic
tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res
72:3499.

49

Robles AI, Bemmels NA, Foraker AB, Harris CC. 2001. APAF1 is a transcriptional target
of p53 in DNA damage-induced apoptosis. Cancer Research 61:6660-4.
Saldanha-Gama RF, Moraes JA, Mariano-Oliveira A, Coelho AL, Walsh EM,
Marcinkiewicz C, Barja-Fidalgo C. 2010. a9B1 integrin engagement inhibits
neutrophil spontaneous apoptosis: Involvement of bcl-2 family members.
Biochimica Et Biophysica Acta 1803:848-57.
Sánchez EE, Lucena SE, Reyes SR, Soto JG, Cantu E, Lopez-Johnston JC, Guerrero B,
Salazar AM, Rodríguez-Acosta A, Galán JA, et al. 2010. Cloning, expression, and
hemostatic activities of a disintegrin, r-mojastin 1, from the mohave rattlesnake
(crotalus scutulus scutulus). Thrombosis Research 126:e211-9.
Schmittgen TD and Livak KJ. 2008. Analyzing real-time PCR data by the comparative
CT method. Nature Protocols 3(6):1101-8.
Seoane AI, Tran VL, Sanchez EE, White SA, Choi JA, Gaytán B, Chavez N, Reyes SR,
Ramos CJ, Tran LH, et al. 2010. The mojastin mutant moj-DM induces apoptosis of
the human melanoma SK-mel-28, but not the mutant moj-NN nor the non-mutated
recombinant moj-WN. Toxicon 56:391-401.
Soengas MS and Lowe SW. 2003. Apoptosis and melanoma chemoresistance. Oncogene
22(20):3138-51.
Soengas MS, Alarcón RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW. 1999.
APAF1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science
284:156-9.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R,
Herman JG, Gerald WL, Lazebnik YA, et al. 2001. Inactivation of the apoptosis
effector APAF1 in malignant melanoma. Nature 409:207-10.
Song L, Coppola D, Livingston S, Cress D, Haura EB. 2005. Mcl-1 regulates survival
and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer
cells. Cancer Biol and Therapy 4(3):267-76.
Streuli CH. 2009. Integrins and cell-fate determination. Jour of Cell Sci 122:171-7.
Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, Zhou X, Ho VC, Trotter MJ.
1998. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin
Cancer Res 4:1865-70.
Teklemariam T, Seoane AI, Ramos CJ, Sanchez EE, Lucena SE, Perez JC, Mandal SA,
Soto JG. 2011. Functional analysis of a recombinant PIII-SVMP, GST-acocostatin;

50

an apoptotic inducer of HUVEC and HeLa, but not sk-mel-28 cells. Toxicon 57:64656.
Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O,
Miyazono K, Noda T, Ichijo H. 2001. ASK1 is required for sustained activations of
JNK/p38 MAP kinases and apoptosis. EMBO Reports 2(3):222-8.
Warr MR and Shore GC. 2008. Unique biology of mcl-1: Therapeutic opportunities in
cancer. Curr Molec Med 8:138-46.
Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ.
1997. Reversion of the malignant phenotype of human breast cells in threedimentional culture and in vivo by integrin blocking antibodies. Jour of Cell Biol
137:231-45.
Wu K, Xie D, Zou Y, Zhang T, Pong R, Xiao G, Fazli L, Gleave M, He D, Boothman
DA, et al. 2013. The mechanism of DAB2IP in chemoresistance of prostate cancer
cells. Clin Cancer Res :1-10.
Xie D, Gore C, Zhou J, Pong R, Zhang H, Yu L, Vessella RL, Min W, Hsieh J. 2009.
DAB2IP coordinates both PI3K-akt and ASK1 pathways for cell survival and
apoptosis. Pnas 106(47):19878-83.
Xie D, Gore C, Liu J, Pong R, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, et
al. 2010. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and
prostate cancer metastasis. Pnas 107(6):2485-90.
Yeh CH, Peng H, Huang T. 1998. Accutin, a new disintegrin, inhibits angiogenesis in
vitro and in vivo by acting as integrin avB3 antagonist and inducing apoptosis.
Blood 92(9):3268-76.
Yoshii Y, Furukawa T, Yoshii H, Mori T, Kiyono Y, Waki A, Kobayashi M, Tsujikawa
T, Kudo T, Okazawa H, et al. 2009. Cytosolic acetyl-CoA sythetase affected tumor
cell survival under hypoxia: The possible function in tumor acetyl-CoA/acetate
metabolism. Cancer Sci 100(5):821-7.
Yuan Y, Nymoen DA, Stavens HT, Rossnes AK, Bjørang O, Wu C, Nesland JM,
Davidson B. 2009. Tenascin-X is a novel diagnostic marker of malignant
mesothelioma. Am J Surg Pathol 33(11):1673-82.
Zarubin T and Han J. 2005. Activation and signaling of the p38 MAP kinase pathway.
Cell Res 15(1):11-8.

51

Zhang H, Zhang R, Luo Y, D'Alessio A, Pober JS, Min W. 2004. AIP1/DAB2IP, a novel
member of the ras-GAP family, transduces TRAF-2induced ASK1-JNK activation. J
Biol Chem 279(43):44955-65.
Zhang R, Zhang H, Lin Y, Li J, Pober JS, Min W. 2007. RIP1-mediated AIP1
phosphorylation at a 14-3-3-binding site is critical for tumor necrosis factor-induced
ASK1-JNK/p38 activation. Jour of Biol Chem 282(20):14788-96.
Zhang R, He X, Liu W, Lu M, Hsieh J, Min W. 2003. AIP1 mediates TNF-a-induced
ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J of
Clin Invest 111(12):1933-43.
Zhang Z, Vuori K, Reed JC, Ruoslahti E. 1995. The a5B1 integrin supports survival of
cells on fibronectin and up-regulates bcl-2 expression. Proc Natl Acad Sci USA
92:6161-5.
Zhuang D, Mannava S, Grachtchouk V, Tang W-H, Patil S, Wawrzyniak JA, Berman
AE, Giordano TJ, Prochownik EV, Soengas MS, Nikiforov MA. 2008. C-MYC
overexpression is required for continuous suppression of oncogene-induced
senescence in melanoma cells. Oncogene 27: 6623-34

52

